A 24-year-old female experiencing hair shedding for 8-9 months suspects it may be due to stress or birth control pills. She plans to consult a dermatologist and gynecologist for further insight.
The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.
Minoxidil can cause initial hair shedding, but it's a sign the treatment is working. Users suggest combining it with finasteride and being patient, as hair often regrows after the shedding phase.
Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.
Finasteride and minoxidil can cause significant initial hair shedding, but regrowth typically follows after a few months. Shedding is not a regular occurrence but may happen to strengthen hair follicles.
The user has been using finasteride weekly for 3 years and regrew most of their hair. They are asking what to expect if they stop using it for 3 weeks.
A 23-year-old male taking 0.25 mg finasteride for 40 days noticed reduced hair shedding and improved hair texture but experienced watery semen, which might be temporary. Overejaculation and finasteride can cause this, and it usually resolves, but consulting a healthcare provider is advised if it persists.
The user is experiencing hair thinning and shedding despite no family history of male pattern baldness. They are considering starting treatments like Minoxidil or finasteride.
The conversation is about the delay in receiving updates on the HMI-115 phase 1 trial for hair loss. No specific treatments are mentioned in the conversation.
The user has been using oral finasteride for about 9 months and oral minoxidil for about 4 months, with some regrowth observed. They are considering a hair transplant and hope to reduce the number of grafts needed by continuing these treatments.
Finasteride can affect hormone levels within two weeks, and a break of several weeks is recommended for baseline results. Monitoring E2 and testosterone is suggested to assess the risk of gynecomastia.
A user shared their 2-year experience with finasteride for hair loss, noting initial success, a period of shedding, and eventual improvement. Another user mentioned seeing no improvement until 14 months in, emphasizing the need for patience.
Hair loss treatments like finasteride and minoxidil need time to work, often taking months. Patience and realistic expectations are crucial for success.
The user is hesitant to use finasteride due to potential hormonal side effects and is waiting for the release of pyrilutamide, a new hair loss treatment. Other users suggest trying finasteride, warning about potential regret if hair loss progresses in the meantime.
Shedding is not necessary for regrowth when using finasteride or dutasteride, as experiences vary. Some users report regrowth without shedding, while others see shedding as a positive sign of future regrowth.
A user is losing hope after 5 months on finasteride, seeing more hair loss and minimal positive changes. Another user advises that shedding is normal and benefits may take up to 2 years.
The user is experiencing diffuse thinning after 10-11 months on oral finasteride and is concerned about whether this is a normal shedding phase. They have been using topical finasteride and minoxidil for over a year.
A user on finasteride for 8 months shared bloodwork results showing increased testosterone and estradiol levels, with concerns about high LH. Responses advised monitoring for symptoms but noted levels are within reference ranges.
A 21-year-old male has been using finasteride 1mg and minoxidil 5% daily for 45 days, noticing some new hair growth but continued hair loss. A reply suggests he is likely shedding and should give it more time for better results.
The user completed their first month using oral finasteride and topical minoxidil without issues but is concerned about a 2-3 day gap in their finasteride supply affecting progress. They are also seeking advice on obtaining a multi-month supply.
PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.
The user experienced significant hair regrowth over eight months using topical minoxidil twice daily and 1mg oral finasteride daily. They also mentioned using a DHT blocker to aid regrowth.
A user shared progress pictures after nearly four months on finasteride, reporting halted shedding and improved hair density. They incorporated a scalp scrubber and Nizoral into their routine, with others sharing similar experiences and encouragement.
The half-life of Dutasteride is commonly stated as around 5 weeks, but some sources suggest it is 170 hours for men aged 20–49, with further information indicating it varies from 3 days to 5 weeks depending on the dose. The user is seeking clarity on these conflicting figures.
The user recovered from Post-Finasteride Syndrome (PFS) using a specific hormone protocol after trying finasteride and dutasteride. They now help others with PFS by reviewing blood work and offering personalized advice.
Maximum serum DHT suppression for finasteride occurs at 8 hours, while for dutasteride, it occurs within 1 to 2 weeks with daily dosing. Dutasteride mesotherapy will be followed by blood tests to check serum DHT changes.
A user is testing clascoterone (Winlevi) on their scalp for hair loss and has noticed a reduction in scalp sebum after one month. They are also using other unspecified treatments and plan to provide an update after the second month.
A user who experienced hair loss and stopped finasteride 4.5 years ago is considering restarting treatment with finasteride and oral minoxidil, questioning if their hair follicles are still recoverable. Responses suggest that hair follicles may not die and can potentially be revived even after many years, with some users sharing personal success stories using treatments like minoxidil, finasteride, microneedling, and RU58841.
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
A user initially had side effects from finasteride, attributed them to anxiety and the nocebo effect, and after resuming the drug, experienced positive effects and now warns against misinformation about Post Finasteride Syndrome.